Other GLP-1 medicines
Older diabetes medicines, other weight-management treatments and medicines still in trials. Check the licensed use for your country before comparing.
Ozempic in the UK: what it treats and how it works
Ozempic's UK licence for type 2 diabetes explained, with how weekly semaglutide works and how Ozempic differs from Wegovy for weight management.
3 min readOther medicinesOzempic doses: the UK starting and increase schedule
How Ozempic starts and increases in the UK, what pen strengths mean, what to do about missed doses and why GLP-1 milligrams do not convert between medicines.
3 min readOther medicinesOzempic safety: side effects, eye symptoms and warning signs
How to tell expected Ozempic stomach side effects from symptoms needing urgent help, including the updated UK eye safety advice on NAION.
3 min readOther medicinesRybelsus: oral semaglutide for type 2 diabetes
What Rybelsus is licensed for in the UK, how oral semaglutide works and how Rybelsus differs from Wegovy tablets for weight management.
3 min readOther medicinesHow to take Rybelsus: fasting, water and other tablets
How to take Rybelsus: fast for at least eight hours, swallow with up to 120 ml of water, wait 30 minutes, and skip a missed tablet.
3 min readOther medicinesRybelsus strengths: 3, 7 and 14 mg now 1.5, 4 and 9 mg
Why Rybelsus 3, 7 and 14 mg tablets became 1.5, 4 and 9 mg, how the strengths match, and why the table does not apply to Wegovy tablets.
3 min readOther medicinesSaxenda in the UK: liraglutide, eligibility and NHS access
Saxenda (liraglutide) is a daily weight-management injection. See who the UK licence covers and why NICE TA664 limits NHS access further.
3 min readOther medicinesUsing a daily Saxenda injection: dose steps and reviews
How to use Saxenda daily: 0.6 mg steps up to 3 mg, injection technique, missed doses, sharps and the adult 5% check after 12 weeks.
3 min readOther medicinesVictoza (liraglutide): diabetes use and UK discontinuation
Victoza is a liraglutide brand for type 2 diabetes. The brand was discontinued in the UK in December 2024 and other liraglutide pens remain.
3 min readOther medicinesTrulicity (dulaglutide) for type 2 diabetes
Trulicity is a weekly dulaglutide injection for type 2 diabetes. See how doses work, what reviews check and how it differs from weight-loss brands.
3 min readOther medicinesByetta: short-acting exenatide for type 2 diabetes
Byetta is a twice-daily exenatide injection for type 2 diabetes, timed around meals. Weekly exenatide is a different product and the two do not swap.
3 min readOther medicinesBydureon: prolonged-release exenatide explained
How weekly Bydureon differs from short-acting Byetta, why its release system sets the schedule and what to check when treatment changes.
3 min readOther medicinesLixisenatide: Lyxumia and insulin combination pens
What lixisenatide does in type 2 diabetes and why a GLP-1-only Lyxumia pen differs from a fixed combination pen that also contains insulin.
3 min readOther medicinesZepbound vs Mounjaro: same tirzepatide, different labels
Why US Zepbound information differs from UK Mounjaro guidance, including the US obesity and obstructive sleep apnoea indications.
3 min readOther medicinesRetatrutide: triple agonist research status in 2026
Retatrutide's three receptor targets, its phase 3 results and planned US filing, and why online research products are not approved medicines.
3 min readOther medicinesCagriSema: semaglutide plus cagrilintide research
What CagriSema contains, how amylin differs from GLP-1 and how to read the REDEFINE and REIMAGINE trial results while it stays investigational.
3 min readOther medicinesSurvodutide: GLP-1 and glucagon research explained
Survodutide's dual glucagon and GLP-1 action, its obesity and liver disease trials, and how 2026 phase 3 results differ from an approval.
3 min readOther medicinesAmycretin, now zenagamtide: what the research shows
The amycretin and zenagamtide names explained, with its GLP-1 and amylin receptor action, oral and injected trials, and its current research status.
3 min read